Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022. The fireside chat is set for February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be accessible on the Investors section of their website, with a replay available for 30 days post-event. Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists targeting hereditary angioedema and aims to provide alternatives to existing injected therapies.

Pharvaris (Nasdaq: PHVS) announced the appointment of Dr. Anne Marie de Jonge Schuermans to its board of directors, replacing Rémi Droller, effective December 22, 2021. Dr. de Jonge Schuermans, with extensive experience in biotech and pharmaceutical operations, will support Pharvaris as it prepares for commercialization of its oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE). The company anticipates a clinical data readout from Phase 2 trials within the next year, marking a pivotal step in its development strategy.

Pharvaris (Nasdaq: PHVS) has appointed Dr. Elisabeth Björk to its board of directors, effective December 1, 2021, to strengthen its leadership ahead of anticipated Phase 2 clinical data releases for hereditary angioedema (HAE) treatments. Dr. Björk, a seasoned expert in drug development at AstraZeneca, is set to replace Martijn Kleijwegt, who stepped down to focus on new investments. This leadership change aims to enhance Pharvaris’s capabilities as it prepares for commercialization of its bradykinin-B2-receptor antagonists candidates, PHVS416 and PHVS719, in the upcoming years.

Pharvaris (Nasdaq: PHVS) continues its robust clinical development with two Phase 2 studies for PHVS416 aimed at treating hereditary angioedema (HAE). The RAPIDe-1 study for on-demand treatment is progressing, while the CHAPTER-1 study for prophylactic treatment is now recruiting patients. Additionally, a Phase 1 pharmacokinetics study for PHVS719 is set to begin this month. Financially, Pharvaris reported cash and equivalents of €218.6 million as of September 30, 2021, marking a significant increase from €98.6 million at year-end 2020. However, R&D expenses rose to €9.0 million, and the quarterly loss was €9.1 million.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on novel oral bradykinin-B2-receptor antagonists, announced its participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. Live audio webcasts will be available on their website, with replays for 30 days following each event.

Pharvaris (Nasdaq: PHVS) reported significant advancements in its clinical programs for PHVS416, a treatment for hereditary angioedema (HAE). The Phase 2 RAPIDe-1 on-demand study is expanding into the US, with data expected in 2022. Additionally, the Phase 2 CHAPTER-1 study for prophylaxis is set to begin in 2021. Financially, the company holds €224.3 million in cash as of June 30, 2021, despite reporting a €15.2 million loss for the quarter. The increase in R&D and G&A expenses highlights the company's growth strategy and investment in clinical studies.

Pharvaris (Nasdaq: PHVS) presented clinical data supporting the safety and pharmacokinetic profile of PHA121 for hereditary angioedema (HAE) at the EAACI Annual Congress 2021. In a double-blind, placebo-controlled study involving 38 healthy volunteers, PHA121 was well-tolerated, with all treatment-emergent adverse events classified as mild. The drug demonstrated dose-proportional absorption with steady-state plasma levels achieved within three days. Pharvaris aims to develop PHA121 into an effective oral treatment for HAE alongside formulations PHVS416 and PHVS719.

Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for oral PHA121, a bradykinin B2 receptor antagonist for hereditary angioedema (HAE), at the EAACI Annual Congress 2021, from July 10-16. The e-Poster will detail the pharmacokinetic profile and tolerability of PHA121 in multiple dose administration. The abstract will be available on the EAACI website on July 10. Pharvaris focuses on developing oral treatments for HAE, aiming to provide alternatives to injected therapies.

Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders scheduled for June 29, 2021, at 1:00 p.m. CEST. Relevant documents, including the notice and agenda, will be accessible in the 'Investors' section of Pharvaris’ website and on the SEC’s site. Pharvaris is focused on developing oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE) and related conditions, offering alternatives to injected therapies. The company's leadership comprises experts in pharmaceutical development and rare disorders.